PRESS RELEASE published on 11/01/2023 at 15:02, 2 years 10 months ago Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000
PRESS RELEASE published on 01/05/2023 at 14:00, 3 years 8 months ago Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
Published on 09/11/2026 at 17:00, 1 hour 34 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 1 hour 34 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 3 hours 9 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 3 hours 34 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 4 hours 4 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 18:15, 18 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 34 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 18:00, 34 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 11 hours 34 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 11 hours 34 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 11 hours 34 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 11 hours 34 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 23 hours 4 minutes ago Availability of the 2026 Interim Financial Report
